Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Clinical Trial of Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

NCT04545762 is registered in ClinicalTrials.gov with C. Babis Andreadis as lead sponsor.

NCT NCT04545762
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04545762 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Clinical Trial of Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Lead sponsor
C. Babis Andreadis
Phase
Phase 1
Overall status
Recruiting
Start date
September 11, 2020
Completion date
October 31, 2026
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

burkitt lymphoma, diffuse large b cell lymphoma, follicular lymphoma, lymphoplasmacytic lymphoma, mantle cell lymphoma, non-hodgkin lymphoma, primary mediastinal large b cell lymphoma, refractory non-hodgkin lymphoma, small lymphocytic lymphoma, transformed lymphoma